Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorLakshmi Nayak, MD
About this trial
This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
Eligibility criteria
Qualifiers
Participants must be able to understand and willing to sign a written informed consent document.
Participant must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.
Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.
Participants must be at least 18 years old on day of signing informed consent.
Disqualifiers
Participants unable to undergo MRI brain.
Participants with active systemic disease.
Participants with uncontrolled intercurrent illness.
Participants with prior exposure to mTOR/PI3K inhibitors
Trial design
Treatments tested in this trial
- PAXALISIB
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Lakshmi Nayak, MD
Lead sponsor
Dana-Farber Cancer Institute
Sponsor institution
Kazia Therapeutics Limited
Collaborator
Source ClinicalTrials.gov